Drug-coated balloon versus drug-eluting stent for treating de novo proximal left anterior descending artery lesions: insights from the REC-CAGEFREE I trial

Authors:
  • ACAiyuan Cheng
    Aiyuan Cheng
  • YWYanqing Wu
    Yanqing Wu
  • FMFangjun Mou
    Fangjun Mou
  • JZJingyu Zhou
    Jingyu Zhou
  • HGHaokao Gao
    Haokao Gao
  • THTao Hu
    Tao Hu
  • DSDongdong Sun
    Dongdong Sun
  • QWQiong Wang
    Qiong Wang
  • HJHong Jiang
    Hong Jiang
  • ZYZhiyong Yin
    Zhiyong Yin
  • SWShangyu Wen
    Shangyu Wen
  • YJYuanzhe Jin
    Yuanzhe Jin

Abstract
BackgroundThe safety and efficacy of drug-coated balloon (DCB) angioplasty for the treatment of proximal left anterior descending (LAD) lesions remain unclear. We aim to assess the prognosis of DCB versus drug-eluting stent (DES) in treating de novo proximal LAD lesions.MethodsREC-CAGEFREE I was an investigator-initiated, multi-center, non-inferiority trial that randomized 2,272 patients to paclitaxel-coated balloon with the option of rescue stenting or second-generation sirolimus-eluting stents for treating de novo lesions, regardless of vessel diameter. In this pre-specified subgroup analysis of the REC-CAGEFREE I study, patients were stratified into two groups based on whether target lesion was located in proximal LAD. The primary endpoint was device-oriented composite endpoint (DoCE, a composite of cardiovascular death, target vessel myocardial infarction, and clinically and physiologically indicated target lesion revascularization) at 2 years.ResultsOf 2,272 patients randomized, 688 (30.3%) had target lesion in proximal LAD. In patients with proximal LAD lesions, compared to DES treatment, DCB treatment had a higher risk of 2-year DoCE (8.8% versus 3.4%, HRIPTW:2.68, 95%CI:1.34-5.35, P=0.008). Similar results were observed in patients with non-proximal LAD lesions (DCB versus DES: 5.4% versus 3.3%, HRIPTW:1.72, 95%CI:1.04-2.85, P=0.038). No significant interaction was observed between the lesion location and the treatment strategy (DES/DCB) (Pinteraction=0.257). In patients with DCB treatment, proximal LAD had a higher risk of DoCE compared to non-proximal LAD (8.8% vs. 5.4%, HRIPTW:1.68, 95%CI:1.01-2.81, P=0.049).ConclusionsDCB treatment was associated with a higher risk of 2-year DoCE compared to DES treatment in patients with target lesion in proximal LAD.